中性粒细胞与淋巴细胞比值对上尿路尿路上皮癌术后出现膀胱复发的预测价值  

Predictive value of neutrophil/lymphocyte ratio for intravesical recurrence after upper urinary tract urothelial carcinoma surgery

作　　者：韩克威 于芹超[1] HAN Kewei;YU Qinchao(Department of Urology,Laoshan District,Affiliated Hospital of Qingdao University,Qingdao,Shandong,266035,China)

机构地区：[1]青岛大学附属医院崂山院区泌尿外科,山东青岛266035

出　　处：《临床泌尿外科杂志》2022年第12期937-941,共5页Journal of Clinical Urology

摘　　要：目的探讨术前中性粒细胞与淋巴细胞比值(NLR)对上尿路尿路上皮癌(UTUC)患者术后出现膀胱内复发(IVR)的预测价值。方法回顾性分析青岛大学附属医院于2011年1月—2017年7月收治317例UTUC患者的临床资料,采用受试者工作特征(ROC)曲线分析NLR最佳截断值,将患者分为低NLR组及高NLR组;利用单因素分析对可能导致UTUC术后出现IVR的危险因素进行分析,将其有意义的因素纳入二元logistics回归分析,筛选出独立危险因素。结果ROC曲线显示NLR最佳截断值为1.877,单因素分析示BMI<18.5 kg/m2或≥24 kg/m2、肿瘤分期、术前行输尿管镜检查、既往或合并膀胱癌、高NLR是UTUC术后出现IVR的危险因素(P<0.05),二元logistic回归分析以上各项均为独立危险因素。结论NLR的获取简易经济,高NLR水平对UTUC患者术后出现IVR具有独立的预测价值。Objective To investigate the predictive value of preoperative neutrophil to lymphocyte ratio(NLR)for postoperative intravesical recurrence(IVR)in patients with upper urinary tract urothelial carcinoma(UTUC).Methods The clinical data of 317 patients with UTUC admitted to Affiliated Hospital of Qingdao University from January 2011 to July 2017 were retrospectively analyzed.The best cut-off value of NLR was analyzed by receiver operating characteristic(ROC)curve.The patients were divided into low NLR group and high NLR group.Univariate analysis was used to analyze the risk factors that may lead to postoperative IVR,and the meaningful factors were included in the binary logistic regression analysis to screen out the independent risk factors.Results ROC curve showed that the best cut-off value of NLR was 1.877.Univariate analysis showed that BMI<18.5 kg/m2 or≥24 kg/m2,tumor stage,preoperative ureteroscopy,previous or combined bladder cancer,and high NLR were the risk factors for postoperative IVR in patients with UTUC.Conclusion The acquisition of NLR is simple and economical.High NLR level has independent predictive value for postoperative IVR in patients with UTUC.

关 键 词：上尿路尿路上皮癌 中性粒细胞与淋巴细胞比值 膀胱内复发 

分 类 号：R737[医药卫生—肿瘤]